Understanding Avadel Pharmaceuticals' Shareholder Interests
Avadel Pharmaceuticals plc, known by its stock ticker NASDAQ: AVDL, is committed to transparency in its operations and shareholder interactions. This article delves into the company's compliance with the Irish Takeover Panel Act, ensuring shareholders and investors are well-informed.
Key Information on Shareholder Disclosure
As per the Irish Takeover Panel guidelines, disclosure of shareholder interests is critical. Here are the main points regarding Avadel Pharmaceuticals:
Full name of discloser: Avadel Pharmaceuticals plc
Owner or controller: Not applicable (N/A)
Name of the offeror/offeree: Avadel Pharmaceuticals plc
Is the discloser an offeror or an offeree? The company serves as the offeree in this context.
Date Position Held
The most recent reporting date is marked on November 4, 2025, without further disclosures associated with additional parties in the offer context.
Shares and Positions
Avadel Pharmaceuticals, in compliance with regulations, disclosed its current interest in shares and related securities as follows:
Interests and Short Positions
The company indicated there were no relevant securities owned or controlled by the discloser. This includes nil holdings across cash-settled and stock-settled derivatives, reinforcing a cautious investment strategy during this period.
Interests of Persons in Concert
Directors and key figures of Avadel Pharmaceuticals possess stakes in the company. Below follows a summary of these interests:
Director Peter Thornton: 104,055 shares (0.11% of total)
Director Linda Palczuk: 67,900 shares (0.07% of total)
Director Geoffrey Glass: 155,979 shares (0.16% of total)
This pattern reflects a modest distribution of shareholdings across the board, indicating controlled management of interests.
Key Takeaways on Corporate Governance
Effective corporate governance underpins Avadel Pharmaceuticals' operations. The company ensures that all interests and short positions are openly disclosed as mandated by international regulations.
Indemnity Arrangements and Other Agreements
Currently, there are no indemnity arrangements or understanding relating to options. Such transparency is vital for maintaining investor confidence and regulatory compliance.
Moreover, no supplemental forms or additional agreements were attached, ensuring a straightforward disclosure process in accordance with their obligations.
Contact Information
For any inquiries or further information, shareholders are encouraged to reach out to Jerad Seurer at +1 636-730-1420. The company remains accessible for any clarifications regarding its shareholder interests and regulatory compliance.
Frequently Asked Questions
What is the current status of Avadel Pharmaceuticals' shares?
Avadel has maintained a stable approach, with no securities currently reported under the ownership of the discloser.
Why is shareholder disclosure important?
Shareholder disclosure is crucial for transparency and trust between the company and its investors, ensuring everyone is informed about ownership structures.
Who can I contact for more information on shareholder positions?
For inquiries regarding shareholder positions, reach out to Jerad Seurer at +1 636-730-1420.
Is there any risk associated with Avadel Pharmaceuticals' stock?
Investors should always assess risks associated with stock performance, particularly when the disclosure report indicates nil interests from the disclosing party.
What are the implications of the recent shareholder disclosures?
The implications promote confidence among investors, signifying that Avadel Pharmaceuticals is adhering to regulations meant to foster trust and accountability.
